By Myles Starr
Medicare Part D beneficiaries and the U.S. government have the potential to save tens of millions of dollars if enrollees buy self-administered oncology drugs using low-cost outlets like Mark Cuban Cost Plus Drug Company (MCCPDC), indicate data published in the Journal of Clinical Oncology (2023 Jun 8. doi:10.1200/JCO.23.00079).
“We demonstrate that Cost Plus Drugs has the potential to improve access to essential cancer medications through reduced out-of-pocket costs for